Tag Archive for: darolutamide
Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxFDA Clears First-in-Human Trial of NSD2 Inhibitor in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxSummary of the PC-BETS Substudy C: Darolutamide in Biomarker-Selected mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxEuropean Commission Approves Darolutamide Plus ADT for Metastatic Hormone-Sensitive Prostate Cancer
/0 Comments/in FDA approvals/by MaxThe European Commission has granted marketing authorization to darolutamide (Nubeqa) combined with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). This approval, following a positive opinion from the European Medicines Agency in June 2025, allows darolutamide plus ADT to be used with or without docetaxel, offering clinicians greater flexibility in tailoring treatment. […]
Triplet therapy shows strongest survival benefit in mHSPC with visceral disease
/0 Comments/in Review/by MaxEarly Results of Gedatolisib and Darolutamide in mCRPC Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxReal-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/0 Comments/in Retrospective studies/by MaxASCO GU 2025: Darolutamide Triplet Therapy Outperforms Alternatives in Advanced Prostate Cancer
/0 Comments/in Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025
- Phase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors August 29, 2025